Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABCL AbCellera Biologics	$3.75 +7.4%	$2.59	$1.89 ▼ $4.09	$1.04B	0.62	3.41 million shs	8.66 million shs
BGM BGM Group	$9.76 -5.4%	$12.56	$5.26 ▼ $17.17	$1.00B	1.29	34,112 shs	37,934 shs
PAHC Phibro Animal Health	$27.94 +5.0%	$23.20	$16.16 ▼ $28.53	$1.08B	0.75	212,994 shs	384,062 shs
TNXP Tonix Pharmaceuticals	$35.17 -5.7%	$29.45	$6.76 ▼ $130.00	$274.42M	2.05	955,849 shs	663,660 shs

7 Stocks to Buy And Hold Forever

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABCL AbCellera Biologics	+1.75%	-5.16%	+72.77%	+57.21%	+25.54%
BGM BGM Group	-2.55%	-20.06%	-22.88%	-6.78%	+1,031,999,900.00%
PAHC Phibro Animal Health	+4.23%	+7.47%	+8.30%	+21.55%	+56.22%
TNXP Tonix Pharmaceuticals	+3.67%	+4.57%	-6.28%	+114.49%	-49.04%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ABCL AbCellera Biologics	2.605 of 5 stars	3.4	1.0	0.0	0.0	2.7	3.3	0.6
BGM BGM Group	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
PAHC Phibro Animal Health	3.6529 of 5 stars	0.8	2.0	2.5	1.1	3.0	3.3	2.5
TNXP Tonix Pharmaceuticals	2.7797 of 5 stars	3.5	2.0	0.0	0.0	1.9	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABCL AbCellera Biologics	2.75	Moderate Buy	$8.33	122.22% Upside
BGM BGM Group	0.00	N/A	N/A	N/A
PAHC Phibro Animal Health	1.67	Reduce	$21.80	-21.98% Downside
TNXP Tonix Pharmaceuticals	3.00	Buy	$585.00	1,563.35% Upside

Current Analyst Ratings Breakdown

Latest TNXP, ABCL, BGM, and PAHC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/25/2025	PAHC Phibro Animal Health	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Equal Weight ➝ Equal Weight	$21.00 ➝ $26.00
6/16/2025	PAHC Phibro Animal Health	BNP Paribas Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
6/16/2025	PAHC Phibro Animal Health	BNP Paribas Exane Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Underperform ➝ Neutral	$24.00
6/3/2025	TNXP Tonix Pharmaceuticals	Alliance Global Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
5/16/2025	ABCL AbCellera Biologics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$28.00 ➝ $10.00
5/8/2025	PAHC Phibro Animal Health	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$20.00 ➝ $21.00
4/16/2025	ABCL AbCellera Biologics	KeyCorp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$4.00 ➝ $5.00
4/15/2025	PAHC Phibro Animal Health	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$20.00

(Data available from 7/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABCL AbCellera Biologics	$28.83M	38.82	N/A	N/A	$3.58 per share	1.05
BGM BGM Group	$25.10M	37.80	N/A	N/A	$7.34 per share	1.33
PAHC Phibro Animal Health	$1.02B	1.11	$2.22 per share	12.59	$6.34 per share	4.41
TNXP Tonix Pharmaceuticals	$10.09M	25.65	N/A	N/A	$31.82 per share	1.11

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABCL AbCellera Biologics	-$162.86M	-$0.56	0.00	N/A	N/A	-737.56%	-15.98%	-12.38%	8/5/2025 (Estimated)
BGM BGM Group	-$1.44M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
PAHC Phibro Animal Health	$2.42M	$0.78	13.79	13.30	0.45	2.68%	30.51%	6.89%	8/27/2025 (Estimated)
TNXP Tonix Pharmaceuticals	-$130.04M	-$1,963.61	0.00	N/A	N/A	-1,313.87%	-120.96%	-101.28%	8/15/2025 (Estimated)

Latest TNXP, ABCL, BGM, and PAHC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/12/2025	Q1 2025	TNXP Tonix Pharmaceuticals	-$3.23	-$2.84	+$0.39	-$2.84	$2.55 million	$2.43 million
5/8/2025	Q1 2025	ABCL AbCellera Biologics	-$0.17	-$0.15	+$0.02	-$0.15	$7.12 million	$4.24 million
5/7/2025	Q3 2025	PAHC Phibro Animal Health	$0.52	$0.63	+$0.11	$0.51	$352.41 million	$347.80 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABCL AbCellera Biologics	N/A	N/A	N/A	N/A	N/A
BGM BGM Group	N/A	N/A	N/A	N/A	N/A
PAHC Phibro Animal Health	$0.48	1.72%	N/A	61.54%	N/A
TNXP Tonix Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Latest TNXP, ABCL, BGM, and PAHC Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
5/6/2025	PAHC Phibro Animal Health	quarterly	$0.12	2.52%	6/4/2025	6/4/2025	6/25/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABCL AbCellera Biologics	N/A	10.15	10.15
BGM BGM Group	N/A	N/A	N/A
PAHC Phibro Animal Health	2.67	2.91	1.23
TNXP Tonix Pharmaceuticals	N/A	12.31	11.64

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABCL AbCellera Biologics	61.42%
BGM BGM Group	N/A
PAHC Phibro Animal Health	99.34%
TNXP Tonix Pharmaceuticals	82.26%

Insider Ownership

Company	Insider Ownership
ABCL AbCellera Biologics	28.90%
BGM BGM Group	58.66%
PAHC Phibro Animal Health	50.07%
TNXP Tonix Pharmaceuticals	0.03%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABCL AbCellera Biologics	500	298.42 million	212.18 million	Optionable
BGM BGM Group	298	97.22 million	40.19 million	N/A
PAHC Phibro Animal Health	1,940	40.53 million	20.24 million	Optionable
TNXP Tonix Pharmaceuticals	50	7.36 million	7.36 million	Not Optionable

TNXP, ABCL, BGM, and PAHC Headlines

Recent News About These Companies

Tonix Pharmaceuticals' Combination Therapy of mTNX-1700 and Anti-PD1 Antibody Shows Promising Results in Gastric Cancer Models

July 2 at 7:55 AM | quiverquant.comQ

Tonix Pharmaceuticals Announces Peer-Reviewed Publication in Cancer Cell Journal Highlighting Positive Preclinical Data of mTNX-1700 in Gastric Cancer Animal Models

July 2 at 7:00 AM | globenewswire.com

Tonix Pharmaceuticals (NASDAQ:TNXP) Stock Price Down 3.7% - Here's Why

July 1 at 3:40 PM | marketbeat.com

Tonix Pharmaceuticals announces inclusion in Russell 3000, Russell 2000 indexes

June 30 at 7:03 PM | msn.com

Tonix Pharmaceuticals (NASDAQ:TNXP) Trading Up 2.4% - Should You Buy?

June 30 at 1:56 PM | marketbeat.com

Tonix Pharmaceuticals to be added to Russell 3000, Russell 2000 indexes

June 30 at 8:14 AM | seekingalpha.com

Tonix Pharmaceuticals Announces Inclusion in the Russell 3000® and Russell 2000® Indexes

June 30 at 7:00 AM | globenewswire.com

Tonix Pharmaceuticals Holding Corp. - TNXP | Barron's

June 29 at 11:44 PM | barrons.com

TNXP | Tonix Pharmaceuticals Holding Corp. Stock Overview (U.S.: Nasdaq) - Barron's

June 27, 2025 | barrons.com

Tonix Pharmaceuticals Holding Corp News (TNXP) - Investing.com

June 27, 2025 | investing.com

Tonix Pharmaceuticals (NASDAQ:TNXP) Stock Price Down 2.4% - Here's Why

June 27, 2025 | marketbeat.com

Tonix Pharmaceuticals (NASDAQ:TNXP) Shares Up 1.7% - Still a Buy?

June 26, 2025 | marketbeat.com

Tonix Pharmaceuticals Holding Corp TNXP Company Vitals - U.S. News

June 26, 2025 | money.usnews.com

TNXP - Tonix Pharmaceuticals Holding Corp News - Morningstar

June 26, 2025 | morningstar.comM

Tonix Pharmaceuticals (NASDAQ:TNXP) Trading Down 3.3% - Time to Sell?

June 25, 2025 | marketbeat.com

Rhumbline Advisers Invests $244,000 in Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)

June 25, 2025 | marketbeat.com

Tonix Pharmaceuticals (NASDAQ:TNXP) Stock Price Up 5% - What's Next?

June 24, 2025 | marketbeat.com

Tonix Pharmaceuticals (NASDAQ:TNXP) Trading Down 2.5% - Should You Sell?

June 23, 2025 | marketbeat.com

Tonix Pharmaceuticals (NASDAQ:TNXP) Trading Down 3% - What's Next?

June 20, 2025 | marketbeat.com

Tonix Pharmaceuticals (NASDAQ:TNXP) Stock Price Down 1.7% - Here's What Happened

June 19, 2025 | marketbeat.com

Tonix Pharmaceuticals (NASDAQ:TNXP) Stock Price Down 1.7% - Time to Sell?

June 18, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

TNXP, ABCL, BGM, and PAHC Company Descriptions

AbCellera Biologics NASDAQ:ABCL

$3.75 +0.26 (+7.45%)

Closing price 04:00 PM Eastern

Extended Trading

$3.73 -0.02 (-0.53%)

As of 07:55 PM Eastern

AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.

BGM Group NASDAQ:BGM

$9.76 -0.56 (-5.43%)

Closing price 04:00 PM Eastern

Extended Trading

$9.82 +0.06 (+0.67%)

As of 06:24 PM Eastern

Qilian International Holding Group Limited manufactures and distributes active pharmaceutical ingredients (APIs), traditional Chinese medicine derivatives (TCMD), and other by-products in China. The company provides licorice products, including Gan Di Xin, an antitussive and expectorant medicine; Qilian Shan Licorice Extract, an ingredient for pharmaceutical companies to manufacture traditional licorice tablets; and Qilian Shan licorice liquid extract, a primary ingredient for medical preparation companies to produce compound licorice oral solutions. It offers Qilian Shan oxytetracycline tablets to prevent and treat a range of diseases in chickens, turkeys, cattle, swine, and human; and Qilian Shan oxytetracycline APIs for pharmaceutical companies to manufacture medications. In addition, the company offers TCMD products, such as Ahan antibacterial paste to treat refractory chronic skin diseases; heparin products, including heparin sodium preparations for pharmaceutical companies to produce medications for cardiovascular diseases, cerebrovascular diseases, and hemodialysis; and Zhu Xiaochang sausage casings, which are natural food products for culinary application. Further, it provides Xiongguan organic fertilizers to improve crop yield and soil's chemical properties and reduce soil compaction; and Xiongguan organic-inorganic compound fertilizers to increased plant growth. Qilian International Holding Group Limited was incorporated in 2019 and is based in Jiuquan, the People's Republic of China.

Phibro Animal Health NASDAQ:PAHC

$27.94 +1.32 (+4.96%)

Closing price 04:00 PM Eastern

Extended Trading

$27.84 -0.10 (-0.36%)

As of 07:29 PM Eastern

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs. It also offers animal health products, such as antibacterials, anticoccidials, nutritional specialty, and vaccines and vaccine adjuvants for animal's health and performance, food safety, and animal welfare; and engages in development, manufacturing, and marketing of microbial and bioproducts for various applications serving animal health and nutrition, environmental, industrial, and agricultural customers. In addition, the company develops, manufactures, and markets conventionally licensed and autogenous vaccine products, as well as adjuvants for animal vaccine manufacturers. Further, it provides formulations and concentrations of trace minerals, such as zinc, manganese, copper, iron, and other compounds to fortify the daily feed requirements of their livestock's diets and maintain optimal balance of trace elements in animals. Additionally, the company offers specialty ingredients for personal care, industrial chemical, and chemical catalyst industries. It sells its animal health and mineral nutrition products through local sales offices to integrated poultry, swine, and cattle producers, as well as through commercial animal feed manufacturers, wholesalers, and distributors. The company was formerly known as Philipp Brothers Chemicals, Inc. and changed its name to Phibro Animal Health Corporation in July 2003. Phibro Animal Health Corporation was founded in 1946 and is headquartered in Teaneck, New Jersey.

Tonix Pharmaceuticals NASDAQ:TNXP

$35.17 -2.13 (-5.71%)

Closing price 04:00 PM Eastern

Extended Trading

$35.43 +0.26 (+0.74%)

As of 07:58 PM Eastern

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults. Its portfolio focuses on central nervous system disorders, as well as rare disease, immunology, and infectious disease product candidates. The company's priority is to submit a New Drug Application (NDA) to the FDA for TNX-102 SL (cyclobenzaprine HCl sublingual tablet), which has completed two positive Phase 3 studies for the management of fibromyalgia. TNX-102 SL is also being developed to treat fibromyalgia-type Long COVID, a chronic post-acute COVID-19 condition. Its TNX-1300 (cocaine esterase) is a biologic designed to treat cocaine intoxication and has been granted breakthrough therapy designation by the FDA. The company's rare disease development portfolio comprises TNX-2900, an intranasal potentiated oxytocin for the treatment of Prader-Willi syndrome (PWS). Its immunology portfolio includes TNX-1500, which is a biologic to address organ transplant rejection and autoimmune diseases. The company's infectious disease pipeline includes TNX-801, a vaccine in development to prevent smallpox and mpox. TNX-801 also serves as the live virus vaccine platform or recombinant pox vaccine platform for other infectious diseases, including TNX-1800 and TNX-1850, in development as a vaccine to protect against COVID-19. Its infectious disease development portfolio also comprises TNX-3900, and TNX-4200 are orally available CD45 antagonists in preclinical development. Tonix Pharmaceuticals Holding Corp. has collaboration agreement with Bilthoven Biologicals to advance TNX-801 mpox vaccine candidate; and with X-Chem, Inc. to develop broad-spectrum antivirals. The company was founded in 2007 and is headquartered in Chatham, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time